Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Petros Nikolinakos (NPI 1306041900)

Field	Value
Entity Type	Individual
Organization	Petros Nikolinakos
Address	3320 Old Jefferson Rd Bldg 800
City	Athens
State	GA
ZIP	30607
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 15, 2007

Payer Source	Total Paid
Medicare	$4.6M
Medicaid	$0

Key Findings

This provider’s Medicare activity is the sole recorded public-payer footprint: Total Medicare revenue is $4.6M while Total Medicaid revenue is none (no Medicaid billing on file), making the practice effectively single-payer (Medicare) in the available data. The top three Medicare codes account for 87.3% of Medicare revenue, indicating a highly concentrated Medicare revenue base.

A9607 is the primary revenue driver for this practice: 11.5K claims produced $2.8M in revenue and represent 61.7% of the provider’s Medicare revenue, reflecting a business focused on radioligand therapeutic services. The code ranks #11 of 44 providers nationally (77th percentile; typical, unremarkable volume for this code), so while A9607 dominates this provider’s revenue mix, the practice is not a national outlier in delivering this specific therapy.

J9271 (pembrolizumab) is the second-largest Medicare contributor with 23.8K claims and $975.8K in revenue, accounting for 21.6% of Medicare revenue. This code ranks #252 of 1841 providers nationally (86th percentile; typical, unremarkable volume for this code), indicating substantial immunotherapy throughput relative to many peers but not a top-tier national volume leader.

99214 (established outpatient E/M) drives meaningful visit volume: 2K claims and $179.8K in revenue (4.0% of Medicare revenue) and is flagged as an extreme outlier, ranking #1264 of 479517 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code). That unusually high E/M volume suggests a heavy follow-up and chronic-care management load consistent with an active oncology practice managing ongoing treatment and surveillance.

The practice’s broader code mix (96413 chemotherapy administration, J0897 denosumab, J1454 antiemetic combo, 96365/96367 infusion codes, and lab/imaging codes such as 85025, 80053, 74177 and 71260) supports a full-service outpatient oncology/hematology operation offering on-site infusion, supportive bone-health treatment, lab monitoring, and imaging coordination. Several supportive codes show notable activity—J0897 has 9.6K claims and $163.2K revenue (3.6% of Medicare revenue) and 96413 has 515 claims and $45.8K revenue—underscoring routine administration and ancillary services around systemic cancer therapy.

There are pockets of elevated national standing on selected ancillary codes: J1454 ranks #22 of 422 providers nationally (95th percentile; notably above typical national volume for this code), 99205 ranks #2566 of 66257 (96th percentile; notably above typical national volume for this code), and 96372 ranks in the 98th percentile (notably above typical national volume). These rankings indicate the provider performs some high-intensity visits and procedures at rates above most peers, consistent with managing complex, high-acuity oncology cases.

Revenue concentration in three codes (A9607, J9271, 99214) accounting for 87.3% of Medicare revenue creates both a clear specialization advantage and a concentration risk: the practice’s financial performance is heavily tied to continued delivery and reimbursement of radioligand therapy and immunotherapy services. Given the absence of Medicaid billing, payer diversification is limited in the available data and could affect payer-negotiation leverage and patient-mix resilience.

The provider’s NPI has been enumerated since 2007-06-15 (~19 years ago), indicating an established presence in the market. Coupled with the high reliance on specialized oncology therapies and elevated E/M encounter volume, this tenure suggests an experienced oncology practice that has built referral and operational capacity to deliver advanced outpatient cancer treatments.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

77 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
A9607	Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie	11,480	$240	$2.8M
J9271	Injection, pembrolizumab, 1 mg	23,800	$40	$975.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,020	$90	$179.8K
J0897	Injection, denosumab, 1 mg	9,600	$20	$163.2K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	150	$320	$47.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	520	$90	$45.8K
J3111	Injection, romosozumab-aqqg, 1 mg	5,880	$10	$41.2K
J1437	Injection, ferric derisomaltose, 10 mg	2,600	$20	$39K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	500	$80	$38.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	510	$60	$30.7K

Showing 1–10 of 77

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 77 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Petros Nikolinakos — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

77 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
A9607	1	10	6,090	$250	$1.6M
J9271	11	40	15,200	$40	$767.3K
J3111	19	20	12,810	$10	$172.9K
J0897	42	290	2,460	$20	$90.2K
J1437	18	30	2,850	$20	$56.4K
J2506	3	10	460	$80	$34.1K
J0885	13	30	3,970	$10	$26.6K
J1454	1	20	80	$330	$25.9K
96413	15	160	170	$90	$20.3K
J3490	19	50	50	$320	$19.8K

Showing 1–10 of 77

Related Providers

Other providers that share a Tax Identification Number (TIN) with Petros Nikolinakos, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Cancer & Blood Center LLC	GA	Hematology & Oncology Physician	$0	$3.2M
Charles Bodine	GA	Hematology & Oncology Physician	$2.3M	$0
Gustavo Westin	FL	Medical Oncology Physician	$2M	$0
James Splichal	GA	Hematology & Oncology Physician	$1.9M	$0
Kuang Chang	GA	Hematology & Oncology Physician	$1.8M	$0
Jeffrey Thomas	GA	Hematology & Oncology Physician	$1.7M	$0
Cynthia Shepherd	GA	Hematology & Oncology Physician	$1.6M	$0
Barry Charnick	FL	Nuclear Radiology Physician	$1.3M	$0
Frederick Flynt	GA	Hematology & Oncology Physician	$1M	$0
Gordon Schoenfeld	GA	Radiation Oncology Physician	$834K	$0

Nearby Providers

Other providers in the same ZIP code as Petros Nikolinakos, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mohan Iyer	GA	Retina Specialist (Ophthalmology) Physician	$1.6M	$0
Victor Copeland	GA	Retina Specialist (Ophthalmology) Physician	$1.5M	$0
Athens Eye Surgery Center,llc	GA	Ambulatory Surgical Clinic/Center	$1.2M	$0
Athens Radiology Associates PC	GA	Diagnostic Radiology Physician	$0	$863K
Tzu-chuan Huang	GA	Hematology & Oncology Physician	$469.2K	$0
Jeffrey Williams	GA	Gastroenterology Physician	$385.8K	$0
Athens Gastroenterology Endoscopy Center Inc	GA	Endoscopy Clinic/Center	$375.9K	$0
Walter Sams	GA	Ophthalmology Physician	$358.3K	$0
Emory Patterson	GA	Ophthalmology Physician	$326.1K	$0
Addie Hill	GA	Hematology & Oncology Physician	$298.2K	$0

Petros Nikolinakos — Billing Profile & Reimbursement Data

Sign up for Petros Nikolinakos — Billing Profile & Reimbursement Data policy alerts

Petros Nikolinakos — Billing Profile & Reimbursement Data

Sign up for Petros Nikolinakos — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References